BellBrook Labs Awarded Patent on Transcreener® HTS Assay for Glycosyltransferases

05 Jan 2011
Share
BellBrook Labs announces that they have been awarded a fourth U.S. patent for their innovative line of Transcreener® HTS Assay kits. This new patent, U.S. 7,847,066, describes the invention of a universal assay for UDP-glycosyltransferases based on direct detection of UDP in a high-throughput format.

There are over 200 glycosyltransferases encoded in the human genome that use either UDP-, GDP- or CMP-activated sugars as the donor substrates. UDP-glycosyltransferases are the most abundant and they play a key role in metabolism of drugs. In the Transcreener® UDP Assay, the detection of UDP produced in the enzyme reaction allows for a universal system to measure UDP-glycosyltransferase activity with any acceptor substrate. Because it allows homogenous, mix-and-read detection, the Transcreener® HTS Assay platform offers significant advantages over other assay methods that require separation steps.

In combination with existing Transcreener® assays for GDP and CMP, the newly patented technology will accelerate the discovery of improved drugs targeting glycosylation events in diseases, such as cancer, type II diabetes and neurodegeneration.

Request Info


Company website

BellBrook Labs